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Abstract We encountered two patients with overlapping
features of primary biliary cholangitis and autoimmune
hepatitis within the same family. A 68-year-old woman
presented at our hospital from a previous medical institu-
tion because of the diagnosis of primary biliary cholangitis.
Her 49-year-old daughter was admitted with liver dys-
function 4 years later. When compared, these two related
patients were found to have overlapping features of pri-
mary biliary cholangitis and autoimmune hepatitis. Their
human leukocyte antigen haplotype was DRB1*04:05/
DRB1*15:02. The clinical and biochemical findings of
these two patients immediately improved following treat-
ment with a combination of prednisolone and ursodeoxy-
cholic acid, in accordance with the Japanese guidelines. It
is extremely important to identify such pathological con-
ditions as quickly as possible, particularly with the
appearance of severe liver dysfunction due to liver cir-
rhosis, as observed in our case. The Japanese guidelines are
considered to be a realistic and useful clinical policy for the
swift and efficient treatment of patients with overlapping
features of primary biliary cholangitis and autoimmune
hepatitis. We suggest that our two patients presented with a
genetic predisposition to autoimmune liver disease with
overlapping features of primary biliary cholangitis and
autoimmune hepatitis within the same family.
Keywords Primary biliary cholangitis  Autoimmune
hepatitis  Overlap syndrome  Familial
Introduction
Primary biliary cholangitis (PBC) and autoimmune hep-
atitis (AIH) are both considered to be autoimmune diseases
of the liver. Although they share the autoimmune aspect,
their pathogenesis, clinical features, disease course, and
response to therapy are quite distinct. PBC is a slowly
progressive disease primarily of the intrahepatic bile ducts,
with a strong preponderance of females and a median age
of 50 years at diagnosis. However, familial PBC is rare
(*1–6 % of PBC cases) and an earlier study suggested that
human leukocyte antigen (HLA)-DR8 represents a risk
factor for developing PBC [1]. Therapy with ursodeoxy-
cholic acid (UDCA) appears to slow the progression of this
disease. On the other hand, AIH is a chronic disorder
characterized by continuing hepatocellular necrosis and
inflammation, usually with fibrosis, which can evolve into
liver cirrhosis and failure. AIH commonly affects young
women, who usually exhibit characteristic autoantibodies
and a characteristic immunogenetic background involving
HLA-B8, DR3, or DR4 [2]. Familial cases of AIH are
reported to occur in only 1 % of AIH cases [3]. Moreover,
response to immunosuppressive therapy is usually prompt
in this disease, resulting in a good long-term prognosis [4].
Patients with overlapping features of PBC and AIH have
been recognized for some time. Although the prevalence of
autoimmune liver disease with overlapping features of
PBC and AIH has been reported to vary considerably
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(2.1–19 %) [5], there are few reports of cases occurring
within the same family. Here we report overlapping fea-
tures of PBC and AIH in the mother and daughter of the
same family.
Case report
Case 1: a 68-year-old woman was admitted to a previous
medical institution because of liver dysfunction. She was
diagnosed with PBC by the following biochemical and
serological findings: aspartate aminotransferase (AST)
212 U/L, alanine aminotransferase (ALT) 203 U/L, total
bilirubin (T-Bil) 0.9 mg/dL, alkaline phosphatase (ALP)
491 U/L, c-glutamyl transpeptidase (c-GTP) 212 U/L,
immunoglobulin (Ig) M 534 mg/dL, and anti-mitochon-
drial antibody (AMA) titer 1:80. Ultrasonography (US)
and computed tomography (CT) showed morphological
changes indicative of liver cirrhosis. Although the patient
was immediately treated with 600 mg UDCA, the
response to this treatment was not sufficient. She was
referred by another medical institution to our hospital for
further, more detailed examinations and was subsequently
admitted to our hospital due to further liver dysfunction
and progressive symptoms over the previous 4 weeks,
including general fatigue, appetite loss, and muscle cramp
in her legs. Her initial laboratory tests revealed liver
dysfunction with an antinuclear antibody (ANA) titer of
1:320 with a homogeneous pattern, and elevation of IgG
to 3,517 mg/dL (Table 1). Serological examinations for
hepatitis A virus (HAV), hepatitis B virus (HBV), and
hepatitis C virus (HCV) were all negative (Table 1).
There was no history of symptoms suggestive of viral
infection. International AIH score on the basis of the
simplified International Autoimmune Hepatitis Group
(IAIHG) scoring system and the revised AIH scoring
system was 6 points and 13 points, respectively, implying
a probable AIH [6, 7]. The HLA-DRB1 haplotype was
DRB1*04:05/DRB1*15:02. Although the patient had
ingested some health foods, liver dysfunction had not
improved when these foods were stopped. Drug-induced
lymphocyte stimulation tests for such food types were
negative. Thus, the patient was eventually diagnosed on
the basis of both the Paris criteria and Japanese guidelines
with an autoimmune liver disease with overlapping fea-
tures of PBC and AIH [4, 8]. We immediately adminis-
tered 5 mg/day prednisolone (PSL) and 600 mg/day of
UDCA [9]. The PSL dose given was smaller than that
indicated by the Japanese guidelines because of the
complication of liver cirrhosis and the consequent
increased risk of opportunistic infections, osteoporosis,
and abnormalities in glucose metabolism. This course of
treatment resulted in improvements to clinical and
biochemical findings within 1 month. Since then, liver
function has remained within the normal range, resulting
in a constant liver cirrhotic condition of Child–Pugh class
A (Fig. 1). Furthermore, the current level of bone mineral
density (BMD) is 0.396 g/cm2 greater than the normal
range (0.261–0.333 g/cm2), although we continue to
administer PSL at a dose of 5 mg/day.
Case 2: a 49-year-old daughter was diagnosed with liver
dysfunction for the first time during medical examinations.
She had a variety of symptoms, including general fatigue
and darkness of the urine for 2 weeks previously. She
visited our hospital and was admitted because of visible
jaundice and laboratory tests indicative of liver dysfunc-
tion: ALT 1425 U/L, AST 1203 U/L, ALP 900 U/L, c-
GTP 208 U/L, T-Bil 4.79 mg/dL, AMA titer 1:40, a posi-
tive AMA-M2 antibody, ANA 1:80 of the speckled type,
and elevation of IgG to 2261 mg/dL (Table 1). Serological
examinations for HAV, HBV, and HCV were all negative
(Table 1). There was no history of symptoms suggestive of
viral infection. The revised AIH score was 14 points,
implying a probable AIH. However, the simplified IAIHG
score was 7 points, implying a definite AIH [6, 7]. US and
CT ruled out obstructive jaundice. The HLA-DRB1 hap-
lotype was DRB1*04:05/DRB1*15:02, as observed with
case 1. There was no history of medication use. Thus, we
eventually diagnosed the patient, on the basis of both the
Paris criteria and Japanese guidelines [4, 8], with an
autoimmune liver disease with overlapping features of
PBC and AIH. Pathological findings from liver biopsies
revealed interface hepatitis with dense portal and periportal
lymphocytic/lymphoplasmacytic infiltrations (Fig. 2). We
immediately treated the patient with a combination of
600 mg/day UDCA and 30 mg/day PSL in accordance
with the Japanese guidelines, which resulted in improve-
ments of both clinical and biochemical findings within
1 month. Since then, liver function has remained normal,
the current BMD is 0.508 g/cm2 greater than the normal
range (0.416–0.488 g/cm2) and PSL has been slowly
reduced to 7.5 mg (Fig. 3).
Familial studies (Table 1): the mother (case 1) has two
children: the first daughter (case 2) and a second daughter.
We tested liver function, autoantibodies, and HLA haplo-
type in all family members and subsequently compared
their clinical backgrounds. The second daughter was
healthy and had no history of liver dysfunction. Laboratory
findings for the second daughter revealed normal liver
function, a negative ANA, and a positive AMA-M2 anti-
body. The first daughter (case 2) had exactly the same HLA
haplotype as the mother (case 1), whereas the second
daughter’s HLA haplotype was DRB1*04:05/
DRB1*01:01. There was no difference between any of the
family members with respect to medication use, smoking
status, alcohol consumption, or obstetric history. The
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Table 1 Laboratory data at the
first medical examination and
comparison of environmental
and genetic factors between all
family members
Case 1 (mother) Case 2 (daughter 1) Daughter 2
Age (years) 68 49 48
Biochemistry
TP (6.5–8.3) (g/dL) 7.8 8.4 7.3
Alb (3.8–5.3) (g/dL) 2.9 3.9 4.4
T.Bil (0.2–1.2) (mg/dL) 4.25 4.79 0.56
AST (5–40) (IU/L) 328 1203 13
ALT (3–35) (IU/L) 312 1425 10
c-GTP (10–60) (IU/L) 60 208 20
ALP (100–340) (IU/L) 418 900 149
Hematology
WBC (4000–8000) (/lL) 3400 5100 6400
RBC (350–480) (9104/lL) 316 446 436
Hb (11.5–16.0) (g/dL) 10.8 14.7 13.8
Plt (12.0–40.0) (9104/uL) 11.8 21.1 26.6
PT % (%) 41.6 79.8 94.0
APTT (26–38) (s) 41.0 35.1 27.7
Serology
IgG (820–1740) (mg/dL) 3517 2261 1249
IgA (90–400) (mg/dL) 370 386 121
IgM (52–270) (mg/dL) 491 203 173
ANA (0–79) 9320 980 \40
AMA (0–19) (980) 940 Not tested
AMA-M2 (0.0–6.9) 161.9 55.8 75.7
ASMA (0–19) \20 \20 Not tested
Anti-LKM1 (0–16.9) \5.0 5.2 Not tested
Viral marker
IgM anti-HA – – Not tested
HBs-Ag – – –
HCV-Ab – – –
IgM anti-HBc (0–0.9) (-) – Not tested
IgG anti-HBc (0–0.99) (-) – Not tested
















Period of time living with
mother
Birth–20 years Birth–20 years
Previous medical history Unremarkable Unremarkable Unremarkable
Medication use Nil Nil Nil
Obstetric history 2 deliveries 3 deliveries 2 deliveries
Serological evidence of past
infection
Epstein–barr virus ? ? Not tested
Cytomegalovirus ? ? Not tested
(-) Serological findings of a previous medical institution, ANA antinuclear antibody, AMA anti-mito-
chondrial antibody, AMA-M2 anti-mitochondrial antibody-M2, ASMA anti-smooth muscle antibody, LKM1
liver–kidney microsome type 1, HLA human leukocyte antigen
Normal ranges given in parentheses
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period of time living with the mother for the first daughter
(case 2) was same as that for the second daughter. The
mother (case 1) was a housewife, which differed from both
daughters’ occupations as nurses. There were no histories
of symptoms suggestive of viral infection.
Discussion
We encountered two patients exhibiting overlapping clin-
ical features of PBC and AIH in a family with a similar
genetic background in terms of HLA-DRB1 haplotype.
Fig. 1 Clinical course of case 1
(mother). Following diagnosis
with an autoimmune liver
disease with overlapping
features of primary biliary
cholangitis and autoimmune
hepatitis, the patient was treated
with a combination of
600 mg/day ursodeoxycholic
acid (UDCA) and 5 mg/day
prednisolone (PSL) in
accordance with the Japanese
guidelines, resulting in the
gradual improvement of both
clinical and biochemical
findings. Key: ANA antinuclear
antibody, AMA-M2 anti-
mitochondrial antibody-M2
Fig. 2 Liver histology for case 2 (daughter). a Liver biopsy showing
severe chronic hepatitis with marked interface hepatitis (92).
b Magnified view of the liver biopsy showing dense lympho-
cytic/lymphoplasmacytic infiltrations in portal tracts and severe
piecemeal necrosis (arrow, 95). c Liver biopsy showing the absence
of bile duct lesions, indicative of chronic nonsuppurative cholangitis
and periductal granuloma (920). d Severe intralobular necrosis and
degeneration of hepatocytes (arrowhead, 920)
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Autoimmune liver disease exhibiting features of both PBC
and AIH may be present at diagnosis or develop during
follow-up. At diagnosis, our cases already fell into two
diagnostic criteria: the Paris criteria and Japanese guideli-
nes [4, 8]. In Japan, most patients with overlapping features
of PBC and AIH have been reported to evolve into either
PBC or AIH [5]. The development of AIH following liver
transplantation for PBC has also been reported [10]. We
suggest that our present cases provide further evidence of a
link between these two diseases. Thus, autoimmune liver
disease with overlapping features of PBC and AIH, the so-
called ‘‘PBC–AIH overlap syndrome,’’ should no longer be
considered as distinct diagnostic entities. However, PBC–
AIH overlap syndrome has been reported to progress
rapidly to cirrhosis and liver failure [11]. In our present
cases, the revised AIH scoring system implied a probable
AIH. On the other hand, based on the simplified IAIHG
scoring system, a probable AIH was implied for case 1, and
a definite AIH for case 2. The simplified IAIHG scoring
system is thought to be more effective in diagnostic
specificity than the revised AIH scoring system [4]. The
relevant scoring system should therefore be selected
depending on the situation and when considering the pos-
sibility of rapid progression when features of PBC and AIH
overlap. In the Japanese guidelines, it is recommended that
physicians treat PBC–AIH overlap syndrome with PSL in
combination with UDCA when PBC patients have also
been described to develop a probable or definite AIH based
on the simplified IAIHG scoring system [4, 6, 12]. In
addition, our cases were diagnosed as definite AIH using
the revised AIH score, which has previously been consid-
ered to exclude a diagnosis of probable AIH for other liver
disorders [7]. Although PBC–AIH overlap syndrome may
not be considered as a distinct diagnostic entity, the ther-
apeutic strategy indicated by the Japanese guidelines is
considered to be a realistic and useful clinical policy to
treat patients with overlapping features of PBC and AIH in
a swift and effective manner, even if they occur within the
same family, as observed in our current cases. Although
our cases responded to PSL therapy, it is necessary to be
careful when patients exhibit a high ALP level, negative
for ASMA and positive for gp210. This is because these
indications represent the possible risk that patients will be
nonresponsive to PSL therapy, as reported previously [13].
Furthermore, the long-term use of PSL can cause adverse
effects, including hyperglycemia, osteoporosis, cataracts,
weight gain, and an increased risk of opportunistic infec-
tions. When treating patients presenting with overlapping
features of PBC and AIH, physicians should be wary about
such complications during follow-up. Fortunately, no
adverse effects arose in either of our two patients as a result
of the long-term use of PSL, although we will have to be
careful with regard to the possibility of such complications
arising over time. The current BMD levels in our two cases
have remained higher than the normal range without
alendronate treatment. However, the administration of
alendronate may be necessary while monitoring BMD, as a
previous study reported that alendronate led to the
improvement of BMD in patients with PBC-related bone
loss [14].
Fig. 3 Clinical course of case 2
(daughter). Liver biopsy was
performed on the day of
admission. Following diagnosis
with an autoimmune liver
disease with overlapping
features of primary biliary
cholangitis and autoimmune
hepatitis, the patient was treated
with a combination of
600 mg/day ursodeoxycholic
acid (UDCA) and 30 mg/day
prednisolone (PSL) in
accordance with the Japanese
guidelines, resulting in an
improvement of both clinical
and biochemical findings within
1 month. Liver function has
remained normal ever since,
despite the subsequent tapering
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It has also been suggested that genetic susceptibility is
an important factor in influencing the course of autoim-
mune liver disease and that HLA type is the most sus-
ceptible genetic factor responsible [1, 3]. Although PBC–
AIH overlap syndrome in white individuals has been
reported to be associated with positive tests for HLA-B8,
DR3, or DR4, which are characterized as HLA haplotypes
for AIH [2], both of our familial occurrence cases shared
the same HLA haplotype, DRB1*04:05/DRB1*15:02. The
second daughter’s HLA haplotype, however, was
DRB1*04:05/DRB1*01:01. It is interesting to note that
DRB1*04:05 was the same within all family members,
whereas the DRB1*01:01 haplotype of the second daughter
differed from the DRB1*15:02 haplotype exhibited by both
case 1 and case 2. While it is well known that the frequency
of the HLA-DRB1*04:05 haplotype is higher in Japanese
AIH patients, it is difficult to accept that the HLA-
DRB1*04:05 haplotype is associated with the susceptibility
to develop overlapping features of PBC and AIH within the
same family. This is because the second daughter, with a
HLA-DRB1*04:05 haplotype, has not developed overlap-
ping features of PBC and AIH in spite of a positive test for
the AMA-M2 antibody. Furthermore, overlapping features
of PBC and AIH within the same family are very rare in
proportion to the high frequency of HLA-DRB1*04:05 in
Japanese AIH patients. On the other hand, the association
of DRB1*15:02, which differed from the second daugh-
ter’s HLA haplotype, with autoimmune liver disease,
including the overlapping features of PBC and AIH within
the same family, remains unknown, although DR15 has
been reported to be associated with other autoimmune
diseases such as systemic lupus erythematosus (SLE)
[4, 15]. Earlier works have shown that SLE is associated
with both AIH and PBC [16, 17]. Considering these con-
ditions, it follows that the HLA-DRB1*15:02 haplotype
may affect the susceptibility to develop overlapping fea-
tures of PBC and AIH within the same family. None of our
present family members had taken any medications to
prevent such problems. Moreover, there are no means of
predicting the onset of PBC and AIH overlap with respect
to alcohol intake, smoking status, occupation, obstetric
history, or viral serology. Although environmental condi-
tions, the use of medications, and a variety of infectious
factors were not considered to have influenced the onset of
disease in either of our two patients, the possibility of their
influences cannot be completely ruled out. As observed in
our two patients, the exact mechanism underlying the onset
of PBC and AIH overlap within the same family remains
unclear. Therefore, it is very important to monitor the
healthy second daughter closely as she was positive for the
AMA-M2 antibody, as this might yield further knowledge
with regard to what factors influence the onset of PBC and
AIH overlap within the same family.
In case 2, pathological findings were compatible with
AIH, in that there were no pathological findings of PBC,
such as chronic nonsuppurative destructive cholangitis.
Therefore, it was considered that AIH might represent a
predominant pathophysiological factor in patients with
overlapping features of PBC and AIH occurring within the
same family, as observed in our cases. PBC patients with a
genetic susceptibility to AIH may occasionally develop a
mixed clinical picture of PBC and AIH. Existing reports
also highlight that a genetic predisposition exists for both
PBC and AIH, which share a common pathogenic mech-
anism [16].
The present cases suggest that a genetic predisposition is
responsible for autoimmune liver disease with overlapping
clinical features of PBC and AIH within the same family. It
has also been reported that AIH develops among PBC
patients after 6 months to 13 years [11]. As observed in our
familial cases, the speed of sequential presentation of
overlapping PBC and AIH features is very rapid. Conse-
quently, autoimmune liver disease with clinical features of
both PBC and AIH occurring within the same family
should be treated very carefully by a combination of PSL
and UDCA immediately, especially considering the pos-
sibility of rapid progression to liver cirrhosis and failure.
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